New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
06:39 EDTDYAXDyax downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Dyax citing a lack of near-term catalysts and keeps a $12 price target for shares.
News For DYAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
16:09 EDTDYAXDyax backs FY15 view of KALBITOR net sales $60M-$70M
Dyax has re-iterated its financial guidance for 2015. Revenue guidance includes two components: KALBITOR net sales in the range of $60M-$70M, reflecting the company's expectation that quarterly and annual KALBITOR net sales will fluctuate due to continued volatility in the level of KALBITOR utilization for individual patients. This volatility in utilization rates is due to fluctuations in the number of HAE attacks experienced by patients and the consistency with which patients treat their HAE attacks with KALBITOR; Development and license fees in the range of $7M-$9M. These fees exclude all potential royalties which would be earned from licensees' sales of LFRP product.
16:08 EDTDYAXDyax reports Q1 EPS (5c), consensus (5c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use